StockData

BridgeBio Pharma vs BioCryst Pharmaceuticals

BBIO and BCRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BBIO and BCRX compare

BridgeBio Pharma is the larger company, worth 7.9 times as much as BioCryst Pharmaceuticals ($15.1B against $1.9B).

BridgeBio Pharma grew revenue faster over the last twelve months (167% versus 68.7% for BioCryst Pharmaceuticals).

BioCryst Pharmaceuticals scores higher on the StockData Score (9 against 3 for BridgeBio Pharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBBIOBCRX
Size and price
Market cap$15.1B$1.9B
Share price$77.36$7.45
Change, 1 year18.9%8.0%
Change, 5 years95.6%−40.3%
Beta (5Y)0.220.59
Employees834435
StockData Score
Total score39 (better)
Valuation score01 (better)
Growth score24 (better)
Performance score02 (better)
Health score12 (better)
Dividend score00
Valuation
P/S15.9×2.0× (better)
P/FCF–5.1×
FCF yield−2.5%19.6% (better)
Growth
Revenue growth (TTM)167% (better)68.7%
Revenue growth, 5Y average127% (better)118%
Profitability
Gross margin94.3%97.8% (better)
Operating margin−38.5%−33.3% (better)
Net margin–−40.9%
FCF margin−39.1%39.7% (better)
Financial health
Interest coverage−7.1×−4.2× (better)
Current ratio2.092.32 (better)
Altman Z-score0.13 (better)−3.84
Piotroski F-score–7
Dividends and buybacks
Buyback yield1.7%–
Shareholder yield1.7% (better)0.00%
Ownership
Held by institutions99.4%103%
Held by insiders35.6%1.9%
Insider net buying, 12 months−$84.8M−$4.1M (better)
Superinvestors holding1–
Short interest, % of float16.6%11.0%

Go deeper

Other comparisons

For information only, not investment advice. Check the source filings before relying on any figure.